Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Research article

Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study

Authors: Cecilia Brain, Steven Kymes, Dana B. DiBenedetti, Thomas Brevig, Dawn I. Velligan

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Treatment-resistant schizophrenia (TRS) affects about one-third of individuals with schizophrenia. People with TRS do not experience sustained symptom relief and at the same time have the most severe disease-related disability and associated costs among individuals with severe mental disorders. Like caregivers of people with treatment-responsive schizophrenia, caregivers of individuals with TRS experience the disease burden along with their care recipients; however, for those providing care for individuals with TRS, the stress of the burden is unrelenting due to uncontrolled symptoms and a lack of effective treatment options. The objective of this study is to better understand the burden of TRS from the caregiver perspective and to explore their perception of available treatments.

Methods

Eight focus groups with non-professional, informal caregivers of individuals with TRS were conducted in 5 US locations. TRS was defined as failure of ≥2 antipsychotics and persistent moderate-to-severe positive symptoms of schizophrenia, per caregiver report.

Results

The 27 caregivers reported an average of 37 h/week providing direct care, and 21 reported being on call “24/7.” Caregivers commonly reported that their care recipients exhibited symptoms of auditory hallucinations (89%), agitation/irritability/hostility (81%), suspiciousness (78%), tangentiality (74%), and cognitive impairment (74%); 70% of caregivers ranked suspiciousness/persecution as the most challenging symptom category. Caring for an individual with TRS impacted many caregivers’ finances, career prospects, social relationships, and sense of freedom. Additionally, multiple medication failures led to a sense of hopelessness for many caregivers.

Conclusions

Persistent positive symptoms caused significant perceived burden, feelings of being overwhelmed and having no relief, and substantial negative impacts on caregivers’ emotional and physical health. To address these substantial unmet needs, policy makers should be aware of the need for practical, social, and emotional support for these caregivers and their families. Additionally, new treatment options for TRS should be developed.
Literature
1.
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.
2.
Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr. 2014;11:3–7.CrossRefPubMed
3.
Tandon R, Targum SD, Nasrallah HA, Ross R. Treatment effectiveness in schizophrenia consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract. 2006;12:348–63.CrossRefPubMed
4.
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M, et al. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65:186–92.CrossRefPubMed
5.
Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M, et al. Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016;173:166–73.
6.
Oda Y, Kanahara N, Iyo M. Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia. Int J Mol Sci. 2015;16:30144–63.CrossRefPubMedPubMedCentral
7.
Suzuki T, Kanahara N, Yamanaka H, Takase M, Kimura H, Watanabe H, et al. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatry Res. 2015;227:278–82.CrossRefPubMed
8.
Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205:1–3.CrossRefPubMed
9.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318–78.CrossRefPubMed
10.
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; steering committee on practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.CrossRefPubMed
11.
12.
Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481–5.CrossRefPubMed
13.
Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, Lindström E, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study. Eur Neuropsychopharmacol. 2013;23:1754–62.CrossRefPubMed
14.
Schöttle D, Karow A, Schimmelmann BG, Lambert M. Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry. 2013;26:384–408.CrossRefPubMed
15.
Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. quiz 47-8PubMed
16.
Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;65:34–48.CrossRef
17.
Jones S, Castle DJ. Management of treatment resistant schizophrenia: a review article. Afr Psychiatry Rev. 2006;9:17–23.
18.
Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63–76.CrossRefPubMed
19.
Brekke JS, Prindel C, Bae SW, Long JD. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv. 2001;52:1358–66.CrossRefPubMed
20.
Gupta S, Isherwood G, Van Impe K. Schizophrenia: bringing the burden of care into the spotlight. 2016.
21.
Millier A, Schmidt U, Angermeyer MC, Chauhan D, Murthy V, Toumi M, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.CrossRefPubMed
22.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.CrossRefPubMed
23.
Ribé JM, Salamero M, Pérez-Testor C, Mercadal J, Aguilera C, Cleris M. Quality of life in family caregivers of schizophrenia patients in Spain: caregiver characteristics, caregiving burden, family functioning, and social and professional support. Int J Psychiatry Clin Pract. 2017:1–9. https://​doi.​org/​10.​1080/​13651501.​2017.​1360500.
24.
Ong HC, Ibrahim N, Wahab S. Psychological distress, perceived stigma, and coping among caregivers of patients with schizophrenia. Psychol Res Behav Manag. 2016;9:211–8.CrossRefPubMedPubMedCentral
25.
Flyckt L, Löthman A, Jörgensen L, Rylander A, Koernig T. Burden of informal care giving to patients with psychoses: a descriptive and methodological study. Int J Soc Psychiatry. 2011;59:137–46.CrossRefPubMed
26.
27.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.CrossRefPubMed
28.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:790–812.
29.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.CrossRef
30.
Brain C, Sameby B, Allerby K, Quinlan P, Joas E, Lindström E, et al. Stigma, discrimination and medication adherence in schizophrenia: results from the Swedish COAST study. Psychiatry Res. 2014;220:811–7.CrossRefPubMed
31.
Allerby K, Sameby B, Brain C, Joas E, Quinlan P, Sjöström N, et al. Stigma and burden among relatives of persons with schizophrenia: results from the Swedish COAST study. Psychiatr Serv. 2015;66:1020–6.CrossRefPubMed
32.
Rabinowitz J, Berardo CG, Bugarski-Kirola D, Marder S. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150:339–42.CrossRefPubMed
33.
Gupta S, Isherwood G, Jones K, Van Impe K. Assessing health status in informal schizophrenia caregivers compared with health status in non-caregivers and caregivers of other conditions. BMC Psychiatry. 2015;15:162.CrossRefPubMedPubMedCentral
34.
Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry. 2002;180:490–5.CrossRefPubMed
35.
Volavka J. Violence in schizophrenia and bipolar disorder. Psychiatr Danub. 2013;25:24–33.PubMed
36.
37.
Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, et al. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006;63:490–9.CrossRefPubMed
38.
Hodgins S, Riaz M. Violence and phases of illness: differential risk and predictors. Eur Psychiatry. 2011;26:518–24.CrossRefPubMed
39.
Nordström A, Kullgren G. Victim relations and victim gender in violent crimes committed by offenders with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2003;38:326–30.CrossRefPubMed
40.
Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.CrossRefPubMedPubMedCentral
41.
Gaynes BN, Brown C, Lux LJ, Brownley K, Van Dorn R, Edlund M, et al. Strategies to de-escalate aggressive behavior in psychiatric patients. 2016. Agency for Healthcare Research and Quality, Rockville, MD, US. Report no.: 16-EHC032-EF. AHRQ Comparative Effectiveness Reviews.
42.
Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663–74.CrossRefPubMed
43.
Fortugno F, Katsakou C, Bremner S, Kiejna A, Kjellin L, Nawka P, et al. Symptoms associated with victimization in patients with schizophrenia and related disorders. PLoS One. 2013;8:e58142.CrossRefPubMedPubMedCentral
44.
Morant N, Kaminskiy E, Ramon S. Shared decision making for psychiatric medication management: beyond the micro-social. Health Expect. 2016;19:1002–14.CrossRefPubMed
45.
Lloyd J, Lloyd H, Fitzpatrick R, Peters M. Treatment outcomes in schizophrenia: qualitative study of the views of family carers. BMC Psychiatry. 2017;17:266.CrossRefPubMedPubMedCentral
46.
Teferra S, Hanlon C, Beyero T, Jacobsson L, Shibre T. Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers. BMC Psychiatry. 2013;13:168.CrossRefPubMedPubMedCentral
47.
Metadata
Title
Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study
Authors
Cecilia Brain
Steven Kymes
Dana B. DiBenedetti
Thomas Brevig
Dawn I. Velligan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1833-5

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue

Research article

ADHD medication in offspring of immigrants — does the income level of the country of parental origin matter?

Research article

A qualitative analysis of suicidal psychiatric inpatients views and expectations of psychological therapy to counter suicidal thoughts, acts and deaths

Research article

Attachment, mentalisation and expressed emotion in carers of people with long-term mental health difficulties

Case report

Possible multiple system atrophy with predominant parkinsonism in a patient with chronic schizophrenia: a case report

Research article

Understanding geographic variations in psychiatric inpatient admission rates: width of the variations and associations with the supply of health and social care in France

Research article

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia